Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
10:14pm, Wednesday, 29'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
04:01pm, Wednesday, 29'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
MindMed Announces New Employee Inducement Grant
04:01pm, Tuesday, 14'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
12:28pm, Tuesday, 14'th Oct 2025
Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extend
Mind Medicine initiated with an Outperform at LifeSci Capital
06:39am, Tuesday, 14'th Oct 2025
LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine with an Outperform rating and $32 price target.
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
02:54pm, Monday, 13'th Oct 2025
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health di
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 22'nd Sep 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidat
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 08'th Sep 2025
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidat
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
MindMed to Participate in September Investor Conferences
07:00am, Thursday, 28'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
03:43am, Tuesday, 12'th Aug 2025
Mind Medicine (MNMD 1.32%) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety dis
MindMed Announces New Employee Inducement Grants
04:01pm, Monday, 11'th Aug 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to trea
1 Reason to Buy MindMed (MNMD)
05:25am, Thursday, 07'th Aug 2025
By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (MNMD 2.59%) is quite a risky play; after all, a key element of its business strategy is
MindMed (MNMD) Q2 Net Loss Jumps 625%
06:43pm, Friday, 01'st Aug 2025
Mind Medicine (MindMed) (MNMD -7.26%), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The compa
